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ABSTRACT Local anesthetics bind to ion channels in a state-dependent manner. For noninactivating voltage-gated K channels
the binding mainly occurs in the open state, while for voltage-gated inactivating Na channels it is assumed to occur mainly in
inactivated states, leading to an allosterically caused increase in the inactivation probability, reﬂected in a negative shift of the
steady-state inactivation curve, prolonged recovery from inactivation, and a frequency-dependent block. How local anesthetics
bind to N-type inactivating K channels is less explored. In this study, we have compared bupivacaine effects on inactivating
(Shaker and Kv3.4) and noninactivating (Shaker-IR and Kv3.2) channels, expressed in Xenopus oocytes. Bupivacaine was found
to block these channels time-dependently without shifting the steady-state inactivation curve markedly, without a prolonged
recovery from inactivation, and without a frequency-dependent block. An analysis, including computational testing of kinetic
models, suggests binding to the channel mainly in the open state, with afﬁnities close to those estimated for corresponding
noninactivating channels (300 and 280 mM for Shaker and Shaker-IR, and 60 and 90 mM for Kv3.4 and Kv3.2). The similar
magnitudes ofKd, as well as of blocking and unblocking rate constants for inactivating and noninactivating Shaker channels, most
likely exclude allosteric interactions between the inactivation mechanism and the binding site. The relevance of these results for
understanding the action of local anesthetics on Na channels is discussed.
INTRODUCTION
Local anesthetics are examples of pharmacological agents
binding to ion channels in a state-dependent manner. The
effects on voltage-gated Na (Nav) channels have been sum-
marized in the modulated-receptor hypothesis, ﬁrst formu-
lated by Hille (1) and Hondeghem and Katzung (2) in 1977.
The main feature of this hypothesis is that the local anesthetic
binds more tightly to inactivated channels than to resting or
open ones, and that the tight binding to inactivated channels
is accompanied by an allosterically induced increase in the
propensity of the channel to inactivate; the inactivation gate
is more likely to be shut when the local anesthetic is bound.
This hypothesis has been extensively used to explain effects
of various local anesthetics on Nav channels of different
origins—the negative voltage shifts of the steady-state in-
activation curve, the slow recovery from inactivation, and the
use-dependent block during repetitive pulsing (3–14).
However, this version of the modulated hypothesis has not
been unchallenged. Other forms, stressing open-state bind-
ing, have also been presented (15–20).
In this context, the action of local anesthetics on inactivating
voltage-gated K (Kv), channels has been surprisingly little
explored, considering the recent advances in understanding the
molecular structure of these channels and their interaction with
blocking molecules (21–28). An obvious experiment in this
context would be to test the modulated receptor hypothesis
developed for Nav channels on inactivating Kv channels, the
prediction being that introducing an inactivated state into a
noninactivating channel increases the afﬁnity for the local
anesthetic.
In this investigation, we analyzed the effects of bupiva-
caine, an amino-amide type local anesthetic widely used for
regional anesthesia, on the rapidly N-type inactivating wild-
type Shaker and Kv3.4 channels (29,30). To explore possible
interactions between the bupivacaine binding and the N-type
inactivation process, we analyzed the bupivacaine effects on
corresponding non-N-type-inactivating channels, a mutated
Shaker isoform (Shaker-IR) and Kv3.2. The latter channel
(Kv3.2) has previously been found to bind bupivacaine
mainly in the open state (31,32).
The experiments on the inactivating channels showed that
bupivacaine causes a time-dependent and relatively voltage-
independent block, without shifting the steady-state inacti-
vation curve markedly (slightly in negative direction) or
prolonging the recovery from inactivation, and thus without
causing use dependence. A kinetic modeling analysis
showed that the block could best be explained by a scheme,
assuming binding exclusively in the open state; no additional
binding in closed or inactivated state is required. At ﬁrst
sight, the mechanisms of local anesthetic action on Kv chan-
nels seem to differ from those on Nav channels. However,
exploring the open-state binding model it can be shown that
assuming a higher afﬁnity, or alternatively faster gating ki-
netics, all the features described for the Nav channel block can
be simulated.
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MATERIALS AND METHODS
Molecular biology
cRNA for the rKv3.2, rKv3.4, Shaker B (in the present study called Shaker)
and Shaker H4 D6-46 (called Shaker-IR) were synthesized by using the
plasmid pAS18 as template for SP6 polymerase (33). rKv3.4 and Shaker
inactivates rapidly while rKv3.2 and Shaker-IR are lacking fast N-type in-
activation. (For the molecular biology of Shaker B and Shaker H4, see
(34,35).) The transcription reactions were performed using a commercial kit
(mMessage mMachine, Ambion, Austin, TX) and T7 RNA polymerase.
Oocytes of the South African clawed toad (Xenopus laevis) were used as
expression system. The oocytes in stage V or VI were injected with the re-
spective cRNA. The injected oocytes were maintained at 12C until used
for experiments. The electrophysiological experiments were performed days
3–5 after injection of cRNA.
Electrophysiology
The investigations were performed with a two-electrode voltage-clamp
technique,modiﬁed to include a concentration-clamp technique (36) andwith
the two-electrode voltage-clamp technique (CA-1 ampliﬁer, Dagan, Minne-
apolis, MN). The pipettes used were of borosilicate glass (Hilgenberg,
Malsfeld, Germany)with a resistance of 0.5–1MVwhen ﬁlledwith 3MKCl.
Data acquisition and analysis were made with pCLAMP software (Axon
Instruments, Foster City, CA). The holding potential was80mV (activation
curves) or100mV(steady-state inactivation curves) and currents associated
with steps as mentioned below.
To avoid a series resistance problem the critical measurements (midpoints)
were performed at relatively low currents. The series resistance problem was
estimated to be negligible in the experiments using the standard setup. In the
concentration-clamp setup, only used for the Kv3 experiments, the volume
resistance of the external solution between membrane and ground was esti-
mated to be between 0.1 and 1 kV (36). A series resistance is predicted to
increase the slope of the activation and inactivation curves, introducing an
error that reduces the absolute value of the shift of activation curve and in-
creases the shift of inactivation curve. Using the higher resistance value
above (1 kV) the error introduced in the values given for the shifts of Kv3
curves can be calculated to be,1.5 mV. The relatively long settling time of
the potential steps (partly due to the large membrane capacitance; (37))
clearly depended on the size of the current. The resulting error was negligible
at currents at ,5 mA, and consequently in the measurements at the used
bupivacaine concentrations. It, however, affected the control currents at high
potential steps. We therefore discarded the ﬁrst 2 ms of these recordings in
the quantitative analysis. The results are given as mean 6 SE.
Solutions
The tissue culture solution used was a modiﬁed Barth’s solution containing
(inmM): NaCl 88, KCl 1, CaCl2 1.5, NaHCO3 2.4,MgSO2 0.8 andHEPES 5,
supplemented with penicillin (100 IU/ml) and streptomycin (100 mg/ml).
pH was adjusted to 7.4 by adding NaOH. The control Ringer solution used
for the electrophysiological experiments on oocytes contained (inmM): NaCl
115, KCl 2, CaCl2 1.8, and HEPES 10. pH was adjusted to 7.2 by adding
NaOH. The test solutions consisted of control solution with bupivacaine
(Sigma Chemical, St. Louis, MO) added.
Analysis
The peak (for inactivating Shaker and Kv3.4 channels) or the steady-state
currents (for noninactivating Shaker-IR and Kv3.2 channels), associated with
steps to 160 mV from a holding potential of 80 mV, were ﬁtted to
IB=Ictrl ¼ 1=ð11 c=IC50Þ; (1)
where IB/Ictrl is the ratio between the current in test solution and in control
solution, c is the bupivacaine concentration, and IC50 is the concentration
blocking 50% of the current. The K conductance of the membrane (G) was
calculated as
GðVÞ ¼ I=ðV1 80Þ; (2)
where V is the membrane potential and I is the current. The steady-state
inactivation curves for the fast inactivating channels in the oocyte experi-
ments were calculated from measurements of the peak currents associated
with holding potentials of 100 mV and a step to120 mV (Shaker) or160
mV (Kv3.4) after conditioning steps of 100 and 400ms duration, respectively.
Computations
The kinetic schemes of the principal blocking mechanisms were extended
versions of the following three-state scheme,
C%
a
b
O%
g
d
I; (Scheme 0)
describing the kinetics of an N-type inactivating K channel. C, O, and I
denote closed, open, and inactivated states, respectively; a, b, g, and d
denote activation, deactivation, inactivation, and deinactivation rate con-
stants, respectively. The activation and deactivation rate constants a and b
were assumed to be voltage-dependent according to
a ¼ keq3 expððV  V1=2Þ=saÞ; (3)
b ¼ keq3 expððV1=2  VÞ=sbÞ; (4)
where keq is the rate constant whenV¼ V1/2; V¼V1/2 whena¼b; and sa and
sb are constants determining the slope of the rate constant versus voltage
curves. The parameter values used are listed in Table 1 and were chosen to
yield a G(V) curve similar to that experimentally obtained with a midpoint at
20 mV and a slope close to 6 mV (e.g., (38)). The inactivation and
deinactivation rate constants g and d are assumed to be voltage-independent
(29,39), and are also listed in Table 1.
The simple one-step activation (in Scheme 0) precludes a sigmoid time
evolution of the open state at depolarization. However, computations with
multistep-activation models gave similar results (see Supplementary Mate-
rial, Fig. S1, Fig. S2, and Fig. S3), and we concluded that the one-step model
was sufﬁcient for the present purpose of exploring binding mechanisms. To
calculate the behavior of a noninactivating Shaker channel mutant (Shaker-
IR), we used a modiﬁed Scheme 0 with the inactivating state removed.
For the numerical analysis, the schemes were expressed as systems of
parallel differential equations, according to the general formula
dPiðtÞ=dt ¼ +
n
j¼0
kji3PjðtÞ  +
n
j¼0
kij3PiðtÞ; (5)
where Pi is the probability that the channel is in state i; n is the number of
conformational states; and kij is the transition rate from state i to state j. The
differential equations were solved by a forward Euler integration method,
using custom-developed software written in BASIC. A time-integration time
step of 0.4–5ms was found adequate to simulate the kinetic curves within the
experimental parameter limits.
TABLE 1 Parameter values used for calculation of kinetic
models of Shaker and Kv3.4
keq V1/2 sa sb g d
(ms1) (mV) (ms1)
Shaker 0.7 20 50 7 0.5 0.03
Kv3.4 0.03 30 50 9 0.024 0.0007
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COMPUTATIONAL RESULTS
Block of noninactivating channels
Fig. 1 A shows the kinetic schemes of three basic ways to
block the two-state noninactivating channel model. The
blocking and unblocking constants were assumed to be
voltage-independent and are denoted k and l, yielding a
dissociation constant Kd¼ l/k. Scheme 1 describes a closed-
state binding mechanism, Scheme 2 an open-state, and
Scheme 3 a state-independent (or all-state) binding mecha-
nism. The effect of bupivacaine on noninactivating Kv1 and
Kv3-type channels is explained by a Scheme 2 mechanism,
while that on Kv2.1 is explained by a version of Scheme 3
(32). A version of Scheme 1 has been suggested to describe
the action of 4-AP (4,40) and tetrahydroaminoacridine (41)
on Kv channels. Fig. 1 B shows the time evolution of the open
probability at 160 mV for the three principal blocking
mechanisms for three levels of blocking rates; slow, inter-
mediate, and fast (k 3 c ¼ l ¼ 0.01, 0.1 and 1 ms1, re-
spectively), assuming the parameter values in Table
1 (Shaker). For Scheme 1 (closed-state binding), the slow
block results in an almost 50% downscaled response, the fast
block in a twofold slower activation rate but otherwise intact
response, and the intermediately fast block in a more than
twofold slower activation. For Scheme 2 (open-state bind-
ing), the slow block results in a slow induced inactivation, the
intermediately fast block in a smaller peak amplitude and an
intermediately fast induced inactivation, and the fast block an
even smaller peak and faster inactivation. Increasing the rate
of block further results in an apparent 50% downscaled re-
sponse (although the activation seems faster). For Scheme 3
(all-state binding), all three block cases result in a 50%
downscaled response.
Fig. 1 C shows the concentration dependence of the three
types of block, assuming an intermediate blocking rate (k 3
c ¼ l ¼ 0.1 ms1). Increasing the concentration decreased
the rate of the rising phase of the closed-state binding model
(Scheme 1), increased the rate of the decaying phase of the
open-state binding model (Scheme 2), and downscaled the
open probability curve of the all-state binding model
(Scheme 3) without affecting the time course.
Block of inactivating channels
To explore the block of channels with fast (N-type) inacti-
vation we used the schemes presented in Fig. 2 A. Fig. 2 B
shows the time evolution of the open probability described by
the four schemes at slow, intermediate, and fast block (k3 c¼
l ¼ 0.01, 0.1, and 1 ms1, respectively) and for the control
situation (no block), assuming V ¼ 160 mV and parameter
values in Table 1 (Shaker). For Scheme 4 (closed-state
binding), the slow block yields roughly a 50% downscaled
FIGURE 1 Principal blocking mecha-
nisms of a noninactivating channel. (A)
Kinetic schemes. C and O denote closed
and open states of the unbound channel, CB
and OB closed and open (but nonconduct-
ing) states of the local anesthetic bound
channel; a, b, k, and l denote rate constants
and c the local anesthetic concentration. (B)
Computed time courses of the open proba-
bility for the different schemes. Calculated
for Kd concentration from Eqs. 3–5, assum-
ing V ¼ 160 mV and using parameter
values in Table 1 (Shaker) for fast, interme-
diate, and slow blocking rates (k ¼ l ¼ 1,
0.1, and 0.01 ms1, respectively). (C) Com-
puted time courses of the open probability
for the different schemes at concentrations
0.3 3 Kd, Kd, and 3 3 Kd, assuming
intermediate blocking rates (k ¼ 0.1 and
l ¼ 0.1 ms1).
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response (as for Scheme 1), and the fast block a less de-
creased peak value and a slowed activation, causing the curve
to cross the control curve. The intermediately fast block re-
sults in a more pronounced peak reduction and a slowed in-
activation. For Scheme 5 (open-state binding), the slow and
intermediate block only results in marginal alterations, while
the fast block reduces the peak and slows down the latter part
of the inactivation, causing the curve to cross the control
curve. For Scheme 6 (inactivated-state binding), all three
blocking cases have almost no effects, and for Scheme 7 (all-
state binding), they all result in a 50% reduction. Combining
Scheme 5 and Scheme 6, assuming equal blocking and un-
blocking rates for the open and inactivated state transitions,
results in a hybrid scheme with properties that are very similar
to those of Scheme 5 except for the important difference that
no crossing-over effect is seen for the fast block (Fig. S4, A
and B).
The magnitude of a steady-state block of inactivating
channels is in real voltage-clamp experiments difﬁcult to es-
timate due to the small currents obtained. In such experiments,
the reduction of the peak current is easier to determine, but
difﬁcult to relate to binding parameters.
Fig. 2 C demonstrates the varying concentration depen-
dencies of the four types of block, assuming an intermediate
rate of blocking (k 3 c ¼ l ¼ 0.1 ms1). Closed-state
(Scheme 4) and all-state (Scheme 7) binding show clear ef-
fects on the peak amplitudes, while open-state (Scheme 5)
binding shows smaller effects at this rate of block and in-
activated-state (Scheme 6) none at all. Open-state (Scheme 5)
binding shows an increased rate of decay with increased
concentration, while closed-state (Scheme 4) binding shows
the reverse. Inactivated-state (Scheme 6) binding shows rel-
atively small effects, while all-state (Scheme 7) binding
shows no effect at all. Analytical expressions of the concen-
tration inﬂuence on the time constants for the decaying phases
in Schemes 4–6 are derived in Appendix B.
Steady-state activation
To obtain curves, reﬂecting the effect of the blocking agent
on steady-state G(V) for the schemes assuming no fast in-
activation, we calculated the steady-state open probabilities
PO(V) at control and Kd (i.e., c ¼ l/k) concentration condi-
tions, using the expressions of Appendix A. The results are
FIGURE 2 Principal blocking mechanisms of an inactivating channel. (A) Kinetic schemes. Symbols as in Fig. 1. I denotes an inactivated state of the
unbound channel and IB the inactivated state of the local anesthetic bound channel; g and d denote the inactivation rate constants and c the local anesthetic
concentration. (B) Computed time courses of the current for the different block schemes. Calculated for Kd concentration from Eqs. 3–5, assuming V ¼ 160
mV and using parameter values in Table 1 (Shaker) for fast, intermediate, and slow blocking rates (k¼ l¼ 1, 0.1, and 0.01 ms1). (C) Computed time courses
of the open probability for the different schemes at concentrations 0.33 Kd, Kd, and 33 Kd, assuming intermediate blocking rates (k¼ 0.1 and l¼ 0.1 ms1).
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shown in Fig. 3A. Scheme 1 results in a14.5mV shift ofG(V)
with no reduction at positive voltages. Scheme 2 results in a
50% reduction of G(V) at positive voltages and in a shift of
4.5 mV. Scheme 3 results in a 50% reduction at all voltages.
Fig. 3 B shows corresponding curves for the schemes that
include fast inactivation: We calculated peak PO(V) curves
assuming intermediately fast binding (k3 c¼ l¼ 0.1ms1).
Open-state binding (Scheme 5) and inactivated-state binding
(Scheme 6), as well as the hybrid scheme constructed from
Scheme 5 and Scheme 6 (see Fig. S4), only marginally affect
the peak values, while closed-state binding (Scheme 4) and
binding in all states (Scheme 7) reduce the values, but without
shifting the curve. In contrast to the distinct effects of different
binding mechanisms on the activation curve of non-
inactivating channels (Fig. 3 A), the corresponding effects on
the activation curve of inactivating channels are relatively
uninformative.
Steady-state inactivation, recovery from
inactivation, and frequency dependence
A more rewarding method to get information about the bind-
ing mechanisms in inactivating channels is to explore the
steady-state inactivation curve for the different cases. A char-
acteristic feature of many local anesthetics is to shift the in-
activation curve in negative direction, traditionally interpreted
as due to a Scheme 6 type binding (i.e., high-afﬁnity binding
to channels in inactivated state (1,42). It can easily be shown,
however, that binding to the channel in the open state, as
described by Scheme 5, also gives a shift in the same direc-
tion (but of a smaller magnitude). Fig. 4 A shows steady-state
inactivation curves for Schemes 4–7 (see Appendix A for
calculations). The parameter values used were the same as
above except for the binding rate, which was k 3 c ¼ 0.5
ms1 (corresponding to a local anesthetic concentration of
53Kd). The calculations show that the different mechanisms
shift (in both directions) and downscale the curves in dif-
ferent combinations. The curve for Scheme 4 (closed-state
binding) is shifted 112 mV and downscaled sixfold, the
curve for Scheme 5 (open-state binding) is shifted 2 mV
without any size reduction, the curve for Scheme 6 (in-
activated-state binding) is shifted 12 mV, also without any
size reduction, and the curve for Scheme 7 (all-state binding)
is downscaled sixfold with no shift.
However, experimental steady-state inactivation curves as
a rule do not show real steady-state values, but are con-
structed from the peak-current values associated with a test
pulse. To mimic experimental inactivation curves we there-
fore calculated the peak open probabilities at a test step after
the conditioning steps. Fig. 4 B shows the results for Schemes
4–7. As seen, the open-state (Scheme 5) binding case devi-
ates somewhat from the steady-state calculation in Fig. 4 A.
However, when normalized (dashed line in Fig. 4 B), the
inactivation curves become almost indistinguishable from
the steady-state curves in Fig. 4 A, thus validating the use of the
simple steady-state calculations when distinguishing binding
mechanisms.
These results may seem to suggest that an open-state block
(Scheme 5) only marginally shifts the inactivation curve.
However, as will be shown in the Discussion, this only holds
for the case assuming a relatively low binding afﬁnity. Thus,
a negative shift of the steady-state inactivation curve alone
does not validate the conclusion that the underlying mecha-
nism is of inactivated-state binding type (Scheme 6); to de-
termine the underlying mechanism, the binding afﬁnity of
blocking agent has to be taken into account.
Another characteristic feature of many local anesthetics
acting on Nav channels is to slow down the rate of recovery
from inactivation, causing use-dependent block. This is, as the
negative shift of the steady-state inactivation curve, tradi-
tionally interpreted as due to a Scheme 6 type blocking (i.e.,
high-afﬁnity binding to channels in inactivated state (42)).
Fig. 4 C shows the time evolution of the recovery to state
C after a pulse step to 120 mV at a Kd concentration for the
four schemes at an intermediate blocking rate (k 3 c ¼ l ¼
0.1ms1). The calculations conﬁrm a slowed recovery for the
inactivated-state binding case (Scheme 6; half-time is more
than doubled), while the recovery for the other schemes
FIGURE 3 Effects of different block mechanisms on activation curves.
Computed steady-state and peak open probability (PO) plotted against
potential for the different blocking schemes (see Figs. 1 and 2), assuming
Kd concentration and intermediate blocking rate. (A) Noninactivating
channels, Schemes 1–3 (see Appendix A). (B) Inactivating channels,
Schemes 4–7.
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(Schemes 4, 5, and 7) is unaffected. The schemes also show
distinctly different concentration dependencies of the recov-
ery time, that of Scheme 6 being most dependent. Fig. 4 D
demonstrates the recovery time course of Scheme 6 at dif-
ferent concentrations. The recovery time courses of the other
schemes at the same three concentrations did not differ
measurably from the control curve (not shown). However, as
will be shown in the Discussion, these results also depend on
the afﬁnity of the substance.
As a consequence of a slowed recovery, many local anes-
thetics acting on Nav channels also induce an increased block
with increased stimulation frequency (i.e., a frequency-de-
pendent or phasic block). Fig. 4 E shows the calculated fre-
quency-dependent decrease of the peak open probability at
120 mV, measured as the open probability associated with
the 20th pulse step divided by the probability associated with
the ﬁrst pulse step, at Kd concentration for the different
blocking schemes. As expected from the results in Fig. 4 E,
three of the schemes do not show any marked use-dependen-
cies (exceeding that of the control curve). Somewhat unex-
pectedly, the curve of the closed-state binding case (Scheme 4)
was shifted upwards. In contrast, and as expected, the curve of
the inactivated-state binding scheme (Scheme 6) was clearly
shifted downwards, demonstrating a marked use-dependence.
Fig. 4 F shows how the concentration affects the use-depen-
dence curves, conﬁrming the concentration sensitivity order of
Fig. 4D, the Scheme 6 curve beingmost affected, the Scheme 4
curve less, the Scheme 5 curve even less, and the Scheme 7
curve not at all. Combining Schemes 5 and 6 into a hybrid
scheme with both open- and inactivated-state binding shows
similarities to Scheme 6 with regard to effects on the steady-
state inactivation and recovery curves (see Fig. S4, C and D).
In conclusion, the kinetic analysis of the effects of different
blocking mechanisms above highlights the need for a careful
analysis when trying to understand the details of local anes-
thetic action. It demonstrates how one and the same binding
FIGURE 4 Effects of different block mechanisms on
steady-state inactivation, recovery from inactivation and
frequency dependence. Computations for Schemes 4–7,
assuming intermediate blocking rates. Except for panel A,
all calculations were made with Eqs. 3–5, using the
parameter values for Shaker in Table 1. (A) Steady-state
inactivation curves according to the expressions in Appen-
dix A, assuming a blocker concentration of 5 3 Kd. (B)
Steady-state inactivation curves for the same cases as in A,
but given as effect on the peak PO, associated with a test
step to 120 mV. (C) Recovery time course of PC at 80
mV after a pulse step to120 mV for the same cases as in A
and B, but assuming a blocker concentration of Kd. (D)
Recovery time course of PC for Scheme 6 at three concen-
trations (0.3 3 Kd, Kd, and 3 3 Kd). Same protocol and
parameter values as in C. The recovery for Schemes 4, 5,
and 7 was not affected by the altered concentrations. (E)
PeakPO versus frequency curves, given as the ratio between
peak PO at the 20th and the 1st step of a pulse train,
consisting of 10 ms pulses to 120 mV from a holding
potential of 80 mV, plotted against frequency. (F) Peak
PO versus frequency curves at the concentrations 0.33 Kd,
Kd, and 3 3 Kd. Same protocol and parameter values as in
E. Control (thick continuous line), Scheme 4 (dashed lines,
highest concentration at top); Scheme 5 (thin continuous
lines, highest concentration at top) and Scheme 6 (dotted
lines, lowest concentration at top).
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model can lead to qualitatively different results depending
on the rate of binding, but also how different models can lead
to very similar results. Thus, a slow closed-state block of an
inactivating channel (Scheme 4) has the same effect as an all-
state block (Scheme 7) of all speeds. The crossing-over
phenomenon is found for a fast closed-state block (Scheme 4)
and for a fast open-state block (Scheme 5).
EXPERIMENTAL RESULTS
The effects of bupivacaine on inactivating
Shaker channels suggest a fast open-state block
Fig. 5 A shows the effect of 300 mM and 1 mM bupivacaine
on the time evolution of the current associated with a pulse
step to 120 mV for inactivating Shaker K channels. The
resulting decay displays an early fast phase and a late slow
phase, leading to the bupivacaine curve crossing the control
curve. A comparative analysis of the time course and the
concentration dependence, using the calculations above (see
Fig. 2), suggests that bupivacaine acts via a fast open-state
block mechanism (Scheme 5). Fig. 5 B shows a calculated
curve, based on Scheme 5, ﬁtted to the experimental data in
Fig. 5 A. The resulting binding rates are listed in Table 2. The
Kd value, obtained from the estimated binding and unbinding
rates (k¼ 1.5 ms13mM1 and l¼ 0.45 ms1) is 300 mM.
(Note that the binding rates are relatively faster than those
used for calculating the curves in Fig. 2 C, leading to larger
amplitude effects in this calculation.)
The bupivacaine induced biphasic decay phase can be ap-
proximated by a sum of two exponential components, while
the decay phase of the control case is approximately mono-
exponential. Fig. 5 C shows inverse time constants for the
single (control) and the fast component (bupivacaine) of the
decay phase of the experimental curves in Fig. 5 A, plotted
against concentration. The values were obtained by ﬁtting a
monoexponential curve to the control curve, and by ﬁtting
sums of two exponentials to the bupivacaine curves. The
continuous curve is the rate of the fast component (the largest
eigenvalue ¼ r2) calculated from the expression derived for
Scheme 5 in Appendix B, plotted against concentration. The
corresponding inverse time constants of Scheme 4 are pre-
dicted to decrease with concentration (see Fig. 2 C and Ap-
pendix B).
Fig. 5 D shows a dose-response curve (Eq. 1) ﬁtted to
measurements of the peak current. The mean IC50 is 1.66 0.1
mM (n ¼ 9; see Table 2), thus 5.3-fold higher than the Kd
value, obtained from ﬁtting Scheme 5 to the current time
course (Fig. 5 B).
Fig. 6 A shows the effect of 1.0 mM bupivacaine (i.e., a
concentration of 3.3 3 Kd mM) on the steady-state inactiva-
tion curve, plotted as the normalized peak current evoked by a
test pulse to 120 mV from different conditioning prepulses
(130 to 10 mV) of 100 ms. The relatively short condi-
tioning pulse duration was used to avoid effects of the C-type
inactivation. The curve is only marginally shifted (3 6
1mV; n¼ 5) as expected from an open-state dependent block
mechanism, but not for an inactivated-state dependent one
(see curves for Scheme 5 and 6 in Fig. 4 B). The continuous
lines show steady-state inactivation curves, calculated from
the equation for Scheme 5 in Appendix A, using values in
Tables 1 and 2.
FIGURE 5 Effect of bupivacaine on time course of
Shaker current. (A) Currents in 300 mM, 1 mM bupiva-
caine, and in control solution evoked from a voltage step to
120 mV. Holding potential was 80 mV. (B) Computed
effect on an inactivating channel, based on Scheme 5 (open-
state binding) and parameter values in Table 1. Resulting
binding rates and dissociation constants are listed in Table
2. (C). Effect of bupivacaine concentration on the fast decay
phase. Inverted time constants (1/t), calculated as eigen-
values (ri) from the matrix equation derived for Scheme 5 in
Appendix B, using the values of Tables 1 and 2, and cor-
responding experimental values, estimated from the curves
in A by ﬁtting a sum of two exponentials to the decaying
phase (between t ¼ 2 and 10 ms), plotted against concen-
tration. The eigenvalue expression used was r2 ¼  1/2 3
(g 1 d1 k3 c1 l1 O((g1 d1 k3 c1 l)2 – 43 (d3
k3 c1 g3 l1 d3 l))). (D) Dose-response curve (Eq. 1)
ﬁtted to mean peak currents at 120 mV (n ¼ 9). Resulting
IC50 ¼ 1.6 mM.
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Fig. 6 B shows the result of applying a twin-pulse recovery
protocol (two 10 ms pulses to 120 mV with a varying inter-
pulse interval at 80 mV) to Shaker channels in control and
300 mM bupivacaine. The quotient between peak currents
measured during the test (second) pulse and during the con-
ditioning (ﬁrst) pulse is plotted as a function of the recovery
time. The current recovers equally fast in control and in bu-
pivacaine in accordance with an open-state block mechanism
(see curve for Scheme 5 in Fig. 4 C). The continuous lines
show recovery curves for the control and the bupivacaine
cases calculated for Scheme 5, using Eq. 5 and the same pa-
rameter values as in Fig. 6A, except for the deinactivation rate
(d), which was slightly adjusted (from 0.03 to 0.024 ms1).
Fig. 6C shows the result of testing the frequency-dependence
of bupivacaine on Shaker. The measurements were used in
two ways; either 1), the quotient between peak currents as-
sociated with the second test pulse and currents associated
with the ﬁrst test pulse was plotted against frequency; or 2),
the quotient between currents associated with the 20th pulse
and currents associated with the ﬁrst pulse. The ﬁrst method
was used to avoid effects of the C-type inactivation. As ex-
pected, considering the results of Fig. 6 A, 300 mM bupiva-
caine did not induce a frequency- or use-dependent block at
any frequencywithin the range studied (2–33 Hz). Such a lack
of extra reduction is predicted by an open-state dependent
mechanism, but not by an inactivated-state dependent mecha-
nism (see curves for Schemes 5 and 6 in Fig. 4 E). This
conclusion was supported by the lack of effect of increasing
the bupivacaine concentration to 1 mM (see Fig. 4 F). The
continuous lines in Fig. 6C are calculated for Scheme 5, using
Eq. 5 and the parameter values used in Fig. 6B. As seen, the ﬁt
between the values based on the second pulse current mea-
surements (ﬁrst method above) was better than that based on
the 20th pulse current measurements (second method above),
suggesting interference from the C-type inactivation in the
latter case.
In conclusion, an open-state block of Scheme 5 type well
explains the observed effects on bupivacaine on the inactivat-
ing Shaker channel. An inactivated-state binding of Scheme 6
type cannot explain the crossing-over phenomenon and a
closed-state binding of Scheme 4 type cannot explain the slight
negative shift of the steady state inactivation curve. Neither can
Scheme 4 nor Scheme 6 explain the induction of an early fast
and late slow inactivation time course by bupivacaine.
The effects of bupivacaine on noninactivating
Shaker channels suggest no allosteric
interaction between inactivation gate and
binding site
A central point in the classical modulated receptor-hypoth-
esis is that the inactivation gate allosterically interacts with
the binding site for the blocking molecule, enhancing the
binding afﬁnity (1). To explore whether this hypothesis ap-
plies to the Shaker channel we used a Shaker channel where
the inactivation gate was genetically deleted (Shaker-IR) and
where the bupivacaine block can be studied in isolation,
without any interference from the N-inactivation process.
Fig. 7 A shows the action of 300 mM and 1 mM bupiva-
caine on the Shaker-IR channel current associated with a
rectangular pulse to 120 mV. The main effect is a general
concentration-dependent reduction. Analyzing the time
courses over a wider voltage range and analyzing G(V)
curves (see below), we conclude that the effect is explainable
by a relatively fast open-state block mechanism (Scheme 2).
Fig. 7 B shows the time courses of model currents corre-
sponding to the currents in Fig. 7 A, calculated for Scheme 2,
using activation values and binding rates listed in Table 2.
Fig. 7 C shows the effects of 300 mM bupivacaine on the
G(V) curve, demonstrating a shift in negative direction (7
mV) and a general downscaling, combined with a slight
voltage dependence at positive voltages. As seen from Fig.
3 A, the negative shift and the general downscaling is pre-
dicted by Scheme 2, but not by a closed-state binding scheme
(Scheme 1), and only the downscaling by an all-state binding
scheme (Scheme 3). Quantifying the predicted effect of 300
mM bupivacaine on the G(V) curve, using the equation for
Scheme 2 in Appendix A, and activation parameter and
binding values in Tables 1 and 2, we obtain a shift of6 mV,
reasonably close to the measured value of 7 mV.
TABLE 2 Estimated activation and binding parameters and mean IC50 for bupivacaine block of Kv channels
Channel type a* (ms1) b* (ms1) k (ms1 mM1) l (ms1) Kd (mM) IC50 (n) (mM) IC50/Kd
Inactivating channels
Shaker 1.0 0 1.5 0.45 0.30 1.6 6 0.1 (9) 5.3
Kv3.4 0.2 0 0.1 0.006 0.06 1.2 6 0.06 (10) 20
Noninactivating channels
Shaker-IR 0.42 0 1.2 0.34 0.28 0.24 6 0.03 (5) 0.86
Kv1.1 0.23 0 0.5 0.10 0.20 0.24 6 0.02 (4) 1.2
Kv1.2 0.27 0 1.2 0.22 0.18 0.21 6 0.02 (12) 1.2
Kv1.5 0.15 0 0.8 0.10 0.12 0.13 6 0.04 (6) 1.1
Kv3.1 0.16 0 0.5 0.06 0.12 0.13 6 0.03 (4) 1.1
Kv3.2 0.17 0 0.5 0.04 0.09 0.11 6 0.02 (5) 1.2
*Value at V ¼160 mV except for Shaker and Shaker-IR, where V ¼120 mV. Values for Kv1.1, 1.2, 1.5, 3.1, and 3.2 from Nilsson et al. (32) included for a
comparison.
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Plotting dose-response data (n ¼ 5) for the steady-state
measurements and ﬁtting them to Eq. 1 yielded a mean IC50
of 0.246 0.03 mM. This is close to the Kd value for the open
channel block of inactivation channels (0.30 mM), but clearly
smaller than the IC50 value for the inactivating channels (1.6
mM, see Table 2). In a previous investigation we have shown
that the bupivacaine action on noninactivating Kv channels is
well described by Scheme 2 (32). The Kd value, obtained
from ﬁtting Scheme 2 to the experimental Shaker-IR data
(time courses and steady-state values) in Fig. 7 A and de-
termination of the binding rates, was 0.28 mM (Table 2),
suggesting that an IC50 measurement reﬂects the binding
afﬁnity.
In conclusion, the results suggest that an open-state block-
ing mechanism of Scheme 2 and Scheme 5 types well ex-
plains the bupivacaine action on both the noninactivating and
inactivating Shaker channels studied here. The close simi-
larity between Kd values and between blocking and un-
blocking rate constants for the two channel types (Table 2)
suggest that the inactivation gate does not allosterically in-
teract with the binding site for bupivacaine.
The effects of bupivacaine on Kv3 channels
suggest a general blocking mechanism for
Kv channels
Can the open-state dependent blocking mechanism, sug-
gested to explain the effects of bupivacaine on the two Shaker
channels, be generalized to other types of Kv channels?
Above, we have analyzed the binding of bupivacaine to a
channelwhen the inactivationmechanism has been artiﬁcially
removed. Since the packing patterns of membrane proteins
are sensitive to mutations and are easily disrupted, we also
wanted to test the effect on channels that have obtained or lost
an inactivation gate by evolutionary processes rather than by
lab-mediated procedures. We therefore chose to compare the
effects of bupivacaine on the closely related Kv3.2 and Kv3.4
(100% identity between their S6 sequences), where Kv3.4 is
inactivating and Kv3.2 is not. As mentioned, bupivacaine has
been shown to block Kv3.2 by an open-state dependent
mechanism of Scheme 2 type (32).
Fig. 8 summarizes some measurements and calculations of
the bupivacaine action on Kv3.4 and Kv3.2 channels, show-
ing that the conclusions from the Shaker experiments can be
transferred to these two channels, suggesting that the bu-
pivacaine effect on Kv channels may be explained by a
common open-state blocking mechanism. Fig. 8 A shows the
FIGURE 6 Effects of bupivacaine on steady-state inactivation, frequency
dependence, and recovery of Shaker current. (A) Steady-state inactivation.
Normalized peak current at a test pulse in 1.0 mM bupivacaine (d) and in
control (s) solution. The currents were evoked by a 50 ms test pulse to120
mV from a conditioning prepulse of 100 ms duration. Mean values from ﬁve
oocytes. Continuous lines are calculations for Scheme 5 (see Appendix A),
using activation and inactivation parameters in Table 1, and binding rates
and dissociation constant in Table 2. (B). Recovery of current after a pulse
step, given as the ratio between peak currents of the second and the ﬁrst step
in a two-step protocol in 300 mM bupivacaine (d) and in control (s)
solution plotted against the interval between the pulses. The pulse protocol
consisted of two 10 ms pulses to 120 mV from a holding potential of 80
mV with a varying interval. Mean values from three-to-ﬁve oocytes.
Continuous lines are calculations for Scheme 5, using Eqs. 3–5 with
activation and inactivation parameter values listed in Table 1, and with
binding rates listed in Table 2. (C). The effect of frequency on the peak
current in 300 mM bupivacaine (d) and in control (s) solution, given as the
ratio between peak currents at the 20th and the ﬁrst step of a pulse train
consisting of 10 ms pulses to120 mV from a holding potential of 80 mV,
plotted against frequency. Also plotted is the ratio between the peak currents
at the second and the ﬁrst step in 300 mM bupivacaine (:) and in control
(n) solution, to show effects without interference from the C-type inacti-
vation. Mean values from three-to-ﬁve oocytes. Continuous lines are
calculations for Scheme 5, using the same equations and parameter values
as in panel B.
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time evolution of the effect of 300 mM and 1 mM bupiva-
caine on the Kv3.4 current associated with a pulse to 160
mV. The shape of the bupivacaine-induced inactivation time
course with a fast and slow phase, causing the curve to cross
the control curve, suggests an open-state block mechanism of
Scheme 5 type (compare to Fig. 2 B). Fig. 8 B shows the
calculated time evolution of the open probability for Scheme
5, with parameters estimated from ﬁtting the curve to the
experimental data in Fig. 8 A (Table 1). The resulting Kd is
60 mM (Table 2).
In the inset, the bupivacaine effect on the fast component
of the biphasic decay phase of the currents in Fig. 8 A is
quantiﬁed. The rate (¼ inverse time constant) of the fast
component, estimated by ﬁtting a sum of two exponentials to
the experimental curve, is plotted against concentration.
Comparing these values with the rates predicted from the
different schemes (Appendix B) shows that open-state
binding (Scheme 5) best explains the data. The continuous
line shows the rate of the fast component (the largest eigen-
value ¼ r2) calculated from the expression derived for
Scheme 5, using parameter values in Tables 1 and 2. Cor-
responding rates for Scheme 4 are predicted to decrease with
concentration (see Fig. 2 C and Appendix B).
Fig. 8 C shows a dose-response curve of ﬁrst-order re-
versible reaction type (Eq. 1) ﬁtted to experimental mean
peak currents (n ¼ 10), yielding an IC50 of 1.2 6 0.1 mM
(Fig. 8 C and Table 2), thus 20-fold higher than corre-
sponding Kd value.
Fig. 8 D shows the effect of 1.0 mM bupivacaine (17-fold
higher concentration than the calculated Kd concentration in
Fig. 8 B) on normalized steady-state inactivation curves of
Kv3.4, measured as the effect on the current evoked by a test
pulse (to 160) from different conditioning prepulses (from
120 to140 mV) of 400 ms. The curve is shifted (measured
as the shift of the curve midpoint, DV1/2)66 2 mV (n¼ 5).
Continuous lines are calculated steady-state inactivation
curves (Appendix A). The resulting midpoint shift is7 mV,
thus well reproducing the experimental data.
Fig. 8 E shows the effect of 300 mM bupivacaine on the
currents of the noninactivating Kv3.2 channel at 160 mV.
The induced modiﬁcations, comprising a fast decay phase,
suggest a relatively fast open-state block mechanism of
Scheme 2 type (compare toFig. 2B). This is strongly supported
by the ﬁnding of a bupivacaine-induced negative shift of the
G(V) curve. Fig. 8 F shows the effect of 100 mM bupivacaine,
displaying a shift of9 mV and a downscaling. Both features
are predicted by Scheme 2 (compare to Fig. 3 A), suggesting
similar blocking mechanisms in the noninactivating Kv3.2 and
Shaker-IR channels. Fitting Scheme 2 calculations to the ex-
perimental currents of Fig. 8 E yields aKd of 90mM (Table 2).
In summary, open-state block schemes (Scheme 2 for
noninactivating channels and Scheme 5 for inactivating
channels), well reproduce the experimental bupivacaine ef-
fects on inactivating and noninactivating Shaker and Kv3-
type channels. Parameter values from the measurements and
the ﬁtting procedures are summarized in Tables 1 and 2,
which also include data from noninactivating Kv channels of
the previous study (32) to show the similar magnitudes of the
parameters of related channels. The similar magnitudes of Kd
as well as of blocking and unblocking rate constants for in-
activating and noninactivating Shaker channels, suggest no
allosteric interference of the inactivation mechanism with the
binding site. The value of Kd for inactivating and non-
inactivating Kv3 channels was of similar magnitude, while
those of the blocking and unblocking rate constants differed
FIGURE 7 Effect of bupivacaine on current time course and G(V) curve
of Shaker-IR. (A) Currents evoked from a voltage step to 120 mV from a
holding potential of 80 mV in 300 mM and 1 mM bupivacaine (d) and in
control (s) solution. (B) Computed time course of the open probability (PO)
of Scheme 2, using activation value and binding rates listed in Table 2. (C)
Corresponding steady-state G(V) curves measured at t ¼ 20 ms (Eq. 2).
Same experiment as in panel A.
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approximately ﬁvefold, suggesting that for these channels the
structure of the binding site or the entry/exit pathways differs
somewhat, despite the sequence identity of the S6 segments,
which form the wall of the internal vestibule, the presumed
binding site of local anesthetics. Nevertheless, the main
conclusion from both the Shaker and the Kv3 experiments
is the same; the introduction of an inactivated state in a non-
inactivating channel does not seem to introduce a new high-
afﬁnity site.
DISCUSSION
Local anesthetics are one of the most widely used pharma-
ceuticals, having a worldwide application in regional anes-
thesia and pain therapy. The clinically relevant effects have
traditionally been attributed to an action onNav channels. The
increasing interest in the effects on Kv channels derives from
two lines of insights. First, exploring the molecular details of
Kv channel effects is today more rewarding than exploring
Nav channel effects due to a better understanding of the
structural details of Kv channels. Second, it is today clear that
direct action on Kv channels may be clinically relevant; sev-
eral cases of pharmacologically induced long QT-syndrome
have been attributed to direct effects on Kv channels
(28,31,43–46). The reasons for exploring the molecular de-
tails of block are many—one, not always sufﬁciently appre-
ciated, being the fact that the molecular mechanism of block
determines the overall effect on neuronal ﬁring patterns, while
it is less discriminative in modulating the action potential.
Different blocking mechanisms (state-dependent or state-in-
dependent binding), causing phenomenologically similar ef-
fects on the single spike level, may lead to totally different
effects on the oscillatory pattern (increased or decreased ﬁring
frequencies) (47).
The dominant, traditional view on local anesthetic action
on Nav channels is the modulated-receptor hypothesis, as-
suming the strongest binding to channels in an inactivated
state and an allosteric interaction between the inactivation
machinery and the binding site (1,2). This view seems chal-
lenged by studies, suggesting a more important role for an
FIGURE 8 Effect of bupivacaine on inactivating and
noninactivating Kv3-type channels. (A) Time course of
Kv3.4 current at a voltage step to 160 mV from a holding
potential of 80 mV in 300 mM and 1 mM bupivacaine,
and in control solution. Note the crossing-over effect at 150
and 220 ms, respectively. (B) Computed time course of the
open probability (Po) of Scheme 5, using activation and
inactivation values listed in Table 1, and binding rates listed
in Table 2. (Inset) Effect of bupivacaine concentration on
the fast component of the decay phase. The continuous line
shows the concentration dependence of inverted time con-
stants (1/t) of the fast component, calculated as largest
eigenvalues from the matrix equation derived for Scheme 5
in Appendix B, using the values of Tables 1 and 2. Solid
circles (d) show experimental values, estimated from the
curves in panel A by ﬁtting a sum of two exponentials to the
decaying phase (between t ¼ 20 and 40 and 200 ms). (C)
Dose-response curve (Eq. 1) ﬁtted to mean peak currents
(d) at 160 mV (n ¼ 10). Resulting IC50 is 1.2 mM. (D)
Steady-state inactivation curve of Kv3.4 in 1.0 mM bupiv-
acaine (d) and in control (s) solution. Measured currents
evoked by a 50 ms test pulse to 130 mV, from a condi-
tioning prepulse of 400 ms duration, plotted versus poten-
tial (n ¼ 5). Continuous lines are calculations for Scheme 5
(see Appendix A). (E) Time course of Kv3.2 current at a
voltage step to 160 mV from a holding potential of 80
mV in 100 and 300 mM bupivacaine, and in control
solution. (F) Steady-state G(V) curves (Eq. 2) for Kv3.2
in 100 mM bupivacaine (d) and in control (s) solution.
Same experiment as in panel E.
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open-state binding (15–18), or that the inactivation gate is
unaffected by the binding process (19,20). Some recent
studies suggest that the traditional view may have to be
complemented; some local anesthetics seem unlikely to bind
to inactivated channels unless the channels have opened ﬁrst
(48,49).
This investigation suggests that bupivacaine blocks the
N-type inactivating Kv channels Shaker and Kv3.4 in a way
that deviates from the traditional modulated-receptor hy-
pothesis, developed for voltage-gated Na channels; it blocks
by binding to channels exclusively in the open state (Scheme
5). This conclusion is based on several lines of evidence. The
time evolution of the block showed crossing-over and a bi-
phasic shape, excluding both closed-state (Scheme 4) and
inactivated-state block (Scheme 6) (see Fig. 2 B). The small,
but negative, shift of steady-state inactivation curves at Kd
concentration excludes closed-state (predicts a positive shift)
and inactivated-state block (predicts a much larger negative
shift) (see Fig. 3 B). The approximately equal Kd values and
equal blocking and unblocking rates for the inactivating and
noninactivating Shaker channels suggest no or a very small
allosteric interaction between the inactivation machinery and
the binding site.
Relevance for the local anesthetic block of
Nav channels
The main difference between the presently observed block-
ing action of bupivacaine on inactivating Kv channels and the
action of the most studied local anesthetics (lidocaine, eti-
docaine, and analogs) on Nav channels is a lower afﬁnity,
reduced effect on recovery from inactivation, a smaller left
shift of the steady-state inactivation curve, and a reduced
effect on use-dependence.
The role of the open-state dependent binding for the block
also seems to differ between the two channel families; while
the present ﬁndings suggest a dominant role for open-state
binding in Kv channels, most studies of local anesthetic ac-
tion on Nav channels suggest that the highest afﬁnity is found
in inactivated channels. However, the situation is not un-
controversial. From the relatively limited number of studies
using the inactivation-removal paradigm, a rather complex
picture emerges: both a dominating afﬁnity for the in-
activated state (3,4,8,50) and a dominating afﬁnity for the
open state (15–18) have been suggested.
The reasons for the different interpretations are many.
Different local anesthetics have different binding afﬁnities,
varying experimental protocols highlight different parame-
ters, and certain procedures (pharmacological inactivation-
removal) may cause structural alterations of the channel
proteins (see Figs. 1 B and 2 B for a clear variation in
blocking action for different blocking rate constants; k3 c¼
l¼ 0.01, 0.1 and 1 ms1, respectively). It may also be due to
differences in the activation and deactivation rate constants of
different channel subtypes.
However, different blocking mechanisms can, under some
circumstances, cause similar effects. Fig. 9 demonstrates how
an open-state block can emulate an inactivated-state block.
Increasing the afﬁnity in the open-state block case (Scheme
5) shown in Fig. 2 (i.e., changing l from l¼ 0.1 ms1 to l¼
0.1/15 ms1), we obtain effects that resemble those of the
inactivated-state block case at a lower afﬁnity (Scheme 6 in
Fig. 2). Thus a 15-fold increase of the afﬁnity (due to a 15-
fold decrease in the unblocking rate), used in the calculations
for the schemes of Fig. 2, shifts the steady-state inactivation
curve 10 mV (Fig. 9 A), prolongs the recovery half-time
approximately twofold (Fig. 9 B), and induces a frequency-
dependent block (Fig. 9 C), making these parameter curves
resemble those of Scheme 6 in Fig. 2.
Thus, a local anesthetic-induced left shift of the inacti-
vation curve or a slowed inactivation-recovery rate does
not, without further investigations, allow us to conclude that
these effects are necessarily caused by an inactivated-state
binding mechanism. Concerning the molecular action of
local anesthetics on Nav channels, we presumably have to
await the crystallization of the channel before the details are
understood.
APPENDIX A: EXPRESSIONS OF STEADY-STATE
ACTIVATION AND INACTIVATION CURVES
FOR THE KINETIC SCHEMES
To calculate the steady-state activation (PO) and inactivation (PC1PO)
curves for the kinetic schemes, describing the different blocking mecha-
nisms, we used the following expressions, where PO is the probability of
being in the open state (O) and PC is the probability of being in the closed
state (C):
POðVÞ ¼ 1=ð11b=a1b=a3 k3 c=lÞ; (Scheme 1)
POðVÞ ¼ 1=ð11b=a1 k3 c=lÞ; (Scheme 2)
POðVÞ ¼ 1=ð11b=aÞ3 1=ð11 k3 c=lÞ; (Scheme 3)
PCðVÞ1POðVÞ ¼ ð11a=bÞ=ð11a=b
1a=b3 g=d1 k3 c=lÞ; (Scheme 4)
PCðVÞ1POðVÞ ¼ ð11a=bÞ=ð11a=b
1a=b3 g=d1a=b3 k3 c=lÞ;
(Scheme 5)
PCðVÞ1POðVÞ ¼ ð11a=bÞ=ð11a=b
1a=b3 g=d1a=b3 g=d3 k3 c=lÞ;
(Scheme 6)
PCðVÞ1POðVÞ ¼ ð11a=bÞ=ð11a=b
1a=b3 g=dÞ3 1=ð11 k3 c=lÞ:
(Scheme 7)
Values of activation and deactivation rate constants (a and b) were obtained
from Eqs. 3 and 4 and parameter values in Table 1, values of inactivation and
deinactivation rate constants (g and d) directly from Table 1, and values of
blocking and unblocking rate constants (k and l) directly from Table 2.
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APPENDIX B: CALCULATING THE
CONCENTRATION-DEPENDENCE OF THE RATE
OF BLOCK
To get analytical expressions for the concentration dependence of the
blocking rates in the kinetic schemes of this investigation we derived
analytical expressions for the eigenvalues of Eq. 5. This equation can be
expressed in following matrix form,
d
dt
PC
PO
PI
PB
2
664
3
775 ¼ M
PC
PO
PI
PB
2
664
3
775;
whereM is a matrix, formed by the rate constants of the kinetic schemes, and
where PC, PO, PI, and PB (see Eq. 5) denote closed (C), open (O), inactivated
(I) and blocked (B) states. Assuming that the blocked state is empty (PB¼ 0)
the matrix M has the following appearance:
M ¼
a b 0 0
a ðb1 gÞ d 0
0 g d 0
0 0 0 0
2
664
3
775:
To describe the kinetic schemes for the block of inactivating channels
(Schemes 4–6) we add the following terms to the matrix elements (Mij):
k3 c toM11; 1 k3 c toM41; 1 l toM14 and  l toM44
(for Scheme 4)
k3 c toM22; 1 k3 c toM42; 1 l toM24 and  l toM44
(for Scheme 5)
k3 c toM33; 1 k3 c toM43; 1 l toM34 and  l toM44
(for Scheme 6):
The solution to the matrix equation above has the following general form,
PiðtÞ ¼ Di1Ei3 expðr13 tÞ1Fi3 exp ðr23 tÞ
1Gi3 expðr33 tÞ;
where Di denotes the steady-state value of Pi(t).
The eigenvalues ri to the matrix above are given by the solutions to the
quartic equation
jr I Mj ¼ 0;
where I is the identity matrix. One of the solutions is always zero, while the
others are nontrivial and rather complex. However, by assuming b ¼ 0, the
system can be simpliﬁed and the solutions are
r0 ¼ 0; r1 ¼ ða1 k3 cÞ; r2;3 ¼ 1=23 ða1 k3 c1 l
6Oðða1 k3 c1 lÞ2  43a3 lÞÞ:
(for Scheme 4)
r0 ¼ 0; r1 ¼ a; r2;3 ¼ 1=23 ðg1 d1 k3 c1 l
6Oððg1 d1 k3 c1 lÞ2  4
3 ðd3 k3 c1 g3 l1 d3 lÞÞÞ:
(for Scheme 5)
r0 ¼ 0; r1 ¼ a; r2;3 ¼ 1=23 ðg1 d1 k3 c1 l
6Oððg1 d1 k3 c1 lÞ2  4
3 ðg3 k3 c1 g3 l1 d3 lÞÞÞ:
(for Scheme 6)
The inverse eigenvalues form the time constants of the phases of the open
probability time course. The expressions above were used to calculate the
concentration-dependence of the fast decaying phase for the kinetic schemes
in Figs. 5 and 8.
FIGURE 9 Effect of increasing the afﬁnity of an open-state blocker.
Computations showing how a open-state block (Scheme 5) can mimic an
inactivated-state block (Scheme 6). The same parameter values as for
corresponding curves in Fig. 4 are used for demonstrating low-afﬁnity
block, while the high-afﬁnity curves are computed with an unblocking rate
of l ¼ 0.1/15 ms1. (A). Steady-state inactivation curves (same protocol as
in Fig. 4 A). The shifts are2 and12 mV, respectively. (B) Time course of
recovery from inactivation (same protocol as in Fig. 4 C). The half-time
values are 22 ms and 44 ms, respectively. (C) Frequency dependence curve
(same stimulation protocol as in Fig. 4 E).
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